Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral VCN-01 with Gemcitabine/Abraxane in Pancreatic Cancer
NCT02045589Phase 1Completed
- Sponsor
- Theriva Biologics
- Start
- Jan 2014
- Primary completion
- Oct 2016
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zabilugene almadenorepvec in pancreatic ductal adenocarcinoma (PDAC), sponsored by Theriva Biologics. Primary endpoints: Safety and Tolerability by means of Adverse Events (AEs) and laboratory data at 6 months and Recommended Phase 2 Dose at 6 months. Started Jan 2014; status: completed.
02
Drugs
zabilugene almadenorepvec
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02045589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045589.